

O I P
JAN 23 2002
JC87

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC10760A				SERIAL NO. 09/883,752					
				APPLICANT J. C. KATH									
				FILING DATE JUNE 18, 2001				GROUP 1614					
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MJ	6	2	2	5	3	1	8	5/2001	Sabolc-Jayne	JAN 28 2002	TECH CENTER 1600	2900	RECEIVED
FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES
													NO
MJ	9	6	1	5	1	1	8	5/96	WIPO				
MJ	9	7	3	0	0	3	4	8/97	WIPO				
MJ	9	9	3	5	1	3	2	7/99	WIPO				
MJ	9	9	3	5	1	4	6	7/99	WIPO				
MJ	0	0	2	1	9	5	5	4/00	WIPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
MJ		Vincent, et al.; Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts; Cancer Chemother Pharmacol; 45:231-238 (2000).											
MJ		Showalter, et al.; Tyrosine Kinase Inhibitors; J. Med. Chem.; 42:5464-5474 (1999).											
MJ		Hennequin, et al.; Design and Structure - Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors; J. Med. Chem.; 42:5369-5389 (1999).											
MJ		Wedge, et al.; ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy; Cancer Research; 60:970-975 (2000).											
EXAMINER		DATE CONSIDERED											
<i>Marij Bar</i>		12/30/02											
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													